Complete reversal of XXXX in experimental @entity5 @entity3085 : Additive effects of @entity723 type II receptor inhibition and beta-2 agonist.

@entity1 @entity2057 @entity5 @entity19 @entity2 @entity3085 @entity815 @entity723 @entity3 @entity6410 @entity12560 @entity4149
UNASSIGNED: @entity6410 is a highly potent b2 -adrenoceptor-selective agonist, which is a muscle growth promoter in many animal species. @entity12560 / @entity723 inhibition reverses skeletal muscle loss and prolongs survival of tumor-bearing animals. The aim of the present investigation was to evaluate the effects of a combination of the soluble @entity12560 receptor ActRIIB (sActRIIB) and the b2 -agonist @entity6410 in the cachectic @entity2 model (LLC). The combination of @entity6410 and sActRIIB was extremely effective in reversing @entity2057 associated with experimental @entity5 @entity3085 in @entity19 . Muscle weights from @entity5 -bearing animals were completely recovered following treatment and this was also reflected in the measured grip strength. This combination increased food intake both in control and @entity5 -bearing animals. The double treatment also prolonged survival significantly without affecting the weight and growth of the primary @entity5 . In addition, it significantly reduced the number of @entity3 . Concerning the mechanisms for the preservation of muscle mass during @entity3085 , the effects of @entity6410 and sActRIIB seemed to be additive, since @entity6410 reduced the rate of protein degradation (as measured in vitro as @entity4149 release, using incubated isolated individual muscles) while sActRIIB only affected protein synthesis (as measured in vivo using tritiated @entity815 ). @entity6410 also increased the rate of protein synthesis and this seemed to be favoured by the presence of sActRIIB. Combining @entity6410 and sActRIIB seemed to be a very promising treatment for experimental @entity5 @entity3085 . Further studies in @entity1 @entity1 are necessary and may lead to a highly effective treatment option for @entity2057 associated with @entity5 . This article is protected by copyright. All rights reserved.
